908 Devices Inc. (MASS)
NASDAQ:MASS
Top Page
908 Devices
(NASDAQ:MASS)
Select Model
Select Model
Rating:58Neutral
Price Target:
$6.50
▲(4.84% Upside)
Action:ReiteratedDate:03/09/26
The score is held back primarily by weak profitability and negative TTM operating/free cash flow, partially offset by a strong, low-leverage balance sheet. The latest earnings call adds support via solid 2026 growth/margin guidance and improving operational traction, while technicals remain mixed and valuation appears relatively inexpensive on P/E but lacks dividend support.
Positive Factors
Balance sheet strength
A strong cash position and low leverage provide durable financial flexibility to fund R&D, absorb cyclical revenue shortfalls, and execute go-to-market expansion without immediate refinancing. This materially reduces solvency risk and supports multi-quarter investment pacing.
Negative Factors
Negative operating cash flow
Persistent negative operating and free cash flow indicate ongoing cash burn despite reported net income improvements. Continued negative cash conversion could force financing, restrict reinvestment, or require slower expansion if internal cash generation does not improve within several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A strong cash position and low leverage provide durable financial flexibility to fund R&D, absorb cyclical revenue shortfalls, and execute go-to-market expansion without immediate refinancing. This materially reduces solvency risk and supports multi-quarter investment pacing.
Read all positive factors
908 Devices (MASS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$260.16M
Dividend YieldN/A
Average Volume (3M)267.03K
Price to Earnings (P/E)9.8
Beta (1Y)1.04
Revenue Growth4.49%
EPS Growth3.61%
CountryUS
Employees246
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.01
Shares Outstanding37,379,950
10 Day Avg. Volume203,138
30 Day Avg. Volume267,027
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)1.32
Price to Sales (P/S)3.38
P/FCF Ratio-7.72
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue3.46
Enterprise Value/Gross Profit6.84
Enterprise Value/Ebitda-6.38
Forecast
1Y Price Target
$8.00Price Target Upside29.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$65.33M
908 Devices Business Overview & Revenue Model
Company Description
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial ...
How the Company Makes Money
908 Devices generates revenue primarily through the sale of its analytical devices and associated software solutions. The company's key revenue streams include direct sales of hardware, ongoing service contracts, and software licenses. Additionall...
908 Devices Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call emphasized clear operational progress: accelerating product adoption (Explorer, Viper), meaningful revenue growth (Q4 +21%, FY +18%), improved margins, a positive Q4 adjusted EBITDA, and a strong cash position ($113M). At the same time, material non‑cash charges influenced full-year reported losses, adjusted EBITDA remains negative for the year, some production and contracting timing risks persist, and planned investments could moderate near‑term margin improvement. Management provided constructive 2026 guidance (15%–20% revenue growth; margin expansion; halving adjusted EBITDA loss), signaling confidence in execution while acknowledging remaining risks.Positive Updates
Quarterly Revenue Growth
Q4 2025 revenue from continuing operations was $17.4M, up 21% year-over-year from $14.3M, driven by demand for Explorer, initial Viper shipments, and U.S. state & local adoption.
Negative Updates
Full-Year Adjusted EBITDA Still Negative
Adjusted EBITDA for full-year 2025 was a loss of $9.6M (although a 39% reduction versus the comparable period cited), indicating progress but ongoing unprofitability on an annual basis.
Read all updates
Q4-2025 Updates
Positive
Negative
Quarterly Revenue Growth
Q4 2025 revenue from continuing operations was $17.4M, up 21% year-over-year from $14.3M, driven by demand for Explorer, initial Viper shipments, and U.S. state & local adoption.
Read all positive updates
Company Guidance
The company guided 2026 revenue to $64.5–$67.5 million (15%–20% growth vs. $56.2M in 2025), driven by a full‑year impact from Viper and MX908, with handheld product and service revenue expected to grow 13%–17% (management cited a handheld range of ~$59.5M–$61.5M), OEM and funded partnerships of about $3M, and AVCAD program revenue of $2M–$3M; it expects adjusted gross margins in the mid‑ to high‑50% range with at least 100 basis points of expansion, plans to cut the 2025 adjusted EBITDA loss (~$9.6M) roughly in half to the mid‑single‑digit millions in 2026, anticipates Q1 growth in the low teens (≈10%–15%) and Q2 nearer the high end (~20%), and is factoring in operational assumptions such as >40 Viper shipments in Q4 (>$3M revenue) with potential 2–3x Viper volumes in 2026, Explorer momentum (150+ units in 2025; ~40% YoY growth), recurring revenue representing ~35% of 2025 sales, and a strong balance sheet ($113M cash, no debt).908 Devices Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 56.20M | 59.63M | 50.23M | 46.85M | 42.21M |
| Gross Profit | 28.42M | 29.93M | 25.32M | 26.02M | 23.23M |
| EBITDA | -21.50M | -43.88M | -40.27M | -31.82M | -20.76M |
| Net Income | 19.49M | -72.21M | -36.40M | -33.56M | -22.17M |
Balance Sheet | |||||
| Total Assets | 190.07M | 159.48M | 202.98M | 242.59M | 260.91M |
| Cash, Cash Equivalents and Short-Term Investments | 112.97M | 69.60M | 145.68M | 188.42M | 224.07M |
| Total Debt | 16.71M | 6.61M | 5.95M | 19.51M | 20.85M |
| Total Liabilities | 46.37M | 44.88M | 37.49M | 51.99M | 46.30M |
| Stockholders Equity | 143.70M | 114.59M | 165.49M | 190.60M | 214.60M |
Cash Flow | |||||
| Free Cash Flow | -24.64M | -30.85M | -27.10M | -22.98M | -29.82M |
| Operating Cash Flow | -23.69M | -30.25M | -25.06M | -20.93M | -29.08M |
| Investing Cash Flow | 50.75M | -46.32M | -26.40M | -15.81M | -737.00K |
| Financing Cash Flow | -697.00K | -376.00K | -15.94M | 1.18M | 94.72M |
908 Devices Technical Analysis
Positive
6.20
Price Trends
6.45
Positive
6.18
Positive
6.64
Positive
Market Momentum
0.12
Negative
62.12
Neutral
84.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MASS, the sentiment is Positive. The current price of 6.2 is below the 20-day moving average (MA) of 6.27, below the 50-day MA of 6.45, and below the 200-day MA of 6.64, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 62.12 is Neutral, neither overbought nor oversold. The STOCH value of 84.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MASS.
908 Devices Risk Analysis
908 Devices disclosed 64 risk factors in its most recent earnings report. 908 Devices reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
908 Devices Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $260.16M | 9.76 | 13.25% | ― | 4.49% | 3.61% | |
52 Neutral | $593.90M | -9.70 | -18.01% | ― | -2.18% | -30.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $278.61M | -2.77 | -104.17% | ― | 31.94% | 36.59% | |
50 Neutral | $259.33M | -6.74 | 137.18% | ― | 49.52% | 19.34% | |
47 Neutral | $154.90M | -2.53 | -29.28% | ― | -2.69% | -149.18% | |
47 Neutral | $147.93M | -4.35 | -32.46% | ― | 15.19% | -3.32% |
* Healthcare Sector Average
MASS
908 Devices
6.96
3.17
83.64%
SENS
Senseonics Holdings
6.67
-4.75
-41.59%
QTRX
Quanterix
3.30
-1.51
-31.39%
NNOX
Nano-X Imaging
2.32
-2.07
-47.15%
TLSI
TriSalus Life Sciences
4.23
-1.32
-23.78%
CTKB
Cytek Biosciences
4.62
1.10
31.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.